104 related articles for article (PubMed ID: 38945552)
1. Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.
Wittling MC; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Cole AC; Lesinski GB; Paulos CM
J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38945552
[TBL] [Abstract][Full Text] [Related]
2. Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.
Wittling MC; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Cole AC; Lesinski GB; Paulos CM
bioRxiv; 2023 Dec; ():. PubMed ID: 38187594
[TBL] [Abstract][Full Text] [Related]
3. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.
Bowers JS; Nelson MH; Kundimi S; Bailey SR; Huff LW; Schwartz KM; Cole DJ; Rubinstein MP; Paulos CM
Clin Cancer Res; 2015 Jun; 21(11):2546-57. PubMed ID: 25904754
[TBL] [Abstract][Full Text] [Related]
4. Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy.
Nissani A; Lev-Ari S; Meirson T; Jacoby E; Asher N; Ben-Betzalel G; Itzhaki O; Shapira-Frommer R; Schachter J; Markel G; Besser MJ
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33990415
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rα
Kim SH; Cho E; Kim YI; Han C; Choi BK; Kwon BS
Nat Commun; 2021 Sep; 12(1):5314. PubMed ID: 34493727
[TBL] [Abstract][Full Text] [Related]
6. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
[TBL] [Abstract][Full Text] [Related]
7.
Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
Rubinstein MP; Cloud CA; Garrett TE; Moore CJ; Schwartz KM; Johnson CB; Craig DH; Salem ML; Paulos CM; Cole DJ
J Am Coll Surg; 2012 Apr; 214(4):700-7; discussion 707-8. PubMed ID: 22360982
[TBL] [Abstract][Full Text] [Related]
9. Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma.
Koike N; Pilon-Thomas S; Mulé JJ
J Immunother; 2008 May; 31(4):402-12. PubMed ID: 18391755
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.
Nelson MH; Bowers JS; Bailey SR; Diven MA; Fugle CW; Kaiser AD; Wrzesinski C; Liu B; Restifo NP; Paulos CM
J Immunother Cancer; 2016; 4():6. PubMed ID: 26885368
[TBL] [Abstract][Full Text] [Related]
11. Effective adoptive transfer of haploidentical tumor-specific T cells in B16-melanoma bearing mice.
Cui NP; Xie SJ; Han JS; Ma ZF; Chen BP; Cai JH
Chin Med J (Engl); 2012 Mar; 125(5):794-800. PubMed ID: 22490577
[TBL] [Abstract][Full Text] [Related]
12. A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy.
Cho HI; Reyes-Vargas E; Delgado JC; Celis E
Cancer Res; 2012 Apr; 72(8):1986-95. PubMed ID: 22367213
[TBL] [Abstract][Full Text] [Related]
13. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.
Kodumudi KN; Weber A; Sarnaik AA; Pilon-Thomas S
J Immunol; 2012 Dec; 189(11):5147-54. PubMed ID: 23100512
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.
Yu Y; Cho HI; Wang D; Kaosaard K; Anasetti C; Celis E; Yu XZ
J Immunol; 2013 Feb; 190(4):1873-81. PubMed ID: 23315072
[TBL] [Abstract][Full Text] [Related]
15. Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis.
Neitzke DJ; Bowers JS; Andrijauskaite K; O'Connell NS; Garrett-Mayer E; Wrangle J; Li Z; Paulos CM; Cole DJ; Rubinstein MP
Cancer Immunol Immunother; 2017 Jun; 66(6):737-751. PubMed ID: 28280853
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8
Johnson CB; May BR; Riesenberg BP; Suriano S; Mehrotra S; Garrett-Mayer E; Salem ML; Jeng EK; Wong HC; Paulos CM; Wrangle JM; Cole DJ; Rubinstein MP
Cancer Res; 2018 Jun; 78(11):3067-3074. PubMed ID: 29636345
[TBL] [Abstract][Full Text] [Related]
17. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
Dudley ME; Yang JC; Sherry R; Hughes MS; Royal R; Kammula U; Robbins PF; Huang J; Citrin DE; Leitman SF; Wunderlich J; Restifo NP; Thomasian A; Downey SG; Smith FO; Klapper J; Morton K; Laurencot C; White DE; Rosenberg SA
J Clin Oncol; 2008 Nov; 26(32):5233-9. PubMed ID: 18809613
[TBL] [Abstract][Full Text] [Related]
18. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
Ma J; Wang YL; Hu HM; Fox BA; Si LS
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.
Boni A; Muranski P; Cassard L; Wrzesinski C; Paulos CM; Palmer DC; Gattinoni L; Hinrichs CS; Chan CC; Rosenberg SA; Restifo NP
Blood; 2008 Dec; 112(12):4746-54. PubMed ID: 18799724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
